Filing Analysis
CVRx, Inc. announced the immediate termination of its Chief Revenue Officer, Robert John, effective August 10, 2026.
🚩 Red Flags
- Immediate termination of a C-suite officer can sometimes indicate internal friction or strategic shifts, though not explicitly stated here.
📋 Key Facts
- Robert John has departed from his role as Chief Revenue Officer (CRO).
- The departure is effective immediately as of August 10, 2026.
- The termination includes severance pay and benefits subject to the terms of his employment agreement.
CVRx, Inc. announced that CFO Jared Oasheim has resigned to pursue other professional opportunities. He will remain in his role until a successor is found, with a transition period extending into a consultancy role through February 2027.
🚩 Red Flags
- Departure of a key financial officer (CFO) can create instability in financial reporting and strategic planning for micro-cap companies.
📋 Key Facts
- Jared Oasheim gave notice of resignation on June 7, 2026.
- Oasheim will remain full-time until the later of August 31, 2026, or 30 days after a successor starts.
- A consulting arrangement is established through February 2027 at a rate of $245 per hour.
- The company will pay Oasheim a cash payment of $262,000 for transition/consulting commitments, split between November 30, 2026, and February 28, 2027.
- Oasheim is eligible for his full 2026 cash incentive payout regardless of termination date.
- The company is currently searching for a successor CFO.
CVRx, Inc. reported the voting results from its 2026 annual meeting of stockholders held on June 1, 2026. The stockholders elected three Class II directors and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the 2026 fiscal year.
📋 Key Facts
- Annual meeting held on June 1, 2026.
- Three Class II directors (Michael Dale, Kevin Hykes, and Joseph Slattery) were elected to serve until the 2029 annual meeting.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 2 (Auditor ratification) received 21,150,201 votes 'For' and 2,275,126 votes 'Against'.
CVRx, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a standard quarterly earnings disclosure under Item 2.02.
📋 Key Facts
- The report was filed on May 11, 2026, covering the fiscal quarter ended March 31, 2026.
- The financial results were disclosed through a press release attached as Exhibit 99.1.
- The information in the filing is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
- CVRx, Inc. is identified as an emerging growth company.
CVRx, Inc. announced preliminary Q1 2026 financial results featuring 20% year-over-year revenue growth and a significant improvement in gross margins to 87%. The company also reported the activation of the first clinical site for its BENEFIT-HF trial and improved reimbursement approval rates following a transition to Category I CPT codes.
🚩 Red Flags
- Operating expenses of $25 million continue to significantly exceed total revenue of $14.8 million, indicating ongoing net losses.
- The financial results are preliminary and unaudited, subject to final adjustments.
📋 Key Facts
- Preliminary Q1 2026 revenue expected between $14.7 million and $14.8 million, a 20% increase over Q1 2025.
- Gross margin improved to approximately 87% compared to 84% in the prior year period.
- Cash and cash equivalents totaled approximately $72.3 million as of March 31, 2026.
- Medicare Advantage 30-day approval rates for prior authorizations increased to 50% in early 2026, up from 31% in 2024.
- The BENEFIT-HF clinical trial activated its first site on March 31, 2026, with enrollment expected to begin in Q2 2026.
- U.S. active implanting centers increased to 257 from 252 at the end of 2025.
CVRx, Inc. granted incremental Performance Stock Units (PSUs) to its executive officers, tied to cumulative revenue targets for the 2026-2027 period. The awards are designed for retention and to incentivize achievement of near-term growth objectives, with final vesting occurring in late 2028.
📋 Key Facts
- Incremental PSU awards granted to all executive officers on February 27, 2026
- Awards are tied to a cumulative revenue goal for the fiscal 2026-2027 performance period
- Grant date value equals 75% of the officers' annual long-term incentives for fiscal 2026
- Vesting occurs 50% upon performance certification and 50% on December 31, 2028
- Payout ranges from 50% to 200% of target based on performance levels
CVRx, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal notice that a press release containing these results was issued on February 12, 2026.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2025.
- Filing date: February 12, 2026.
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
CVRx, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to facilitate an 'at-the-market' (ATM) offering of common stock. The company intends to sell up to $50 million in shares to fund working capital and general corporate purposes.
🚩 Red Flags
- Potential dilution for existing shareholders due to the ATM offering.
- Use of proceeds for 'working capital and general corporate purposes' often indicates a need for immediate liquidity/cash runway extension.
📋 Key Facts
- Entered into a Sale Agreement with Jefferies LLC on January 12, 2026.
- Aggregate offering amount is up to $50.0 million.
- The offering is an 'at-the-market' (ATM) program under Rule 415.
- Agent (Jefferies LLC) will receive a commission of up to 3.0% of gross proceeds.
- Proceeds are earmarked for working capital and general corporate purposes.
- The offering is based on a Form S-3 registration statement declared effective on December 15, 2025.
CVRx, Inc. amended its existing loan agreement to increase available credit by $50 million (up to a $100 million aggregate) and extended the maturity date to May 9, 2031. The company also reported preliminary full-year 2025 revenue growth of 10-11% and provided details on its upcoming BENEFIT-HF clinical trial.
🚩 Red Flags
- Increased debt load with significant interest rate margins (6.75% + margin).
- Performance covenants remain in place, requiring 50% of trailing 12-month revenue targets.
- Significant future capital expenditure required for BENEFIT-HF trial ($20M-$30M).
📋 Key Facts
- Amended Loan Agreement: Increased available loans by $50 million, bringing the aggregate principal amount up to $100 million.
- Interest Rate Adjustment: Floating rate equal to the greater of prime or 6.75%, plus a margin of 2.65% (margin decreases to 2.00% upon achieving two consecutive quarters of positive adjusted EBITDA).
- Maturity Extension: Term loan maturity extended to May 9, 2031; interest-only period extended to four years.
- New Debt Incurred: Borrowed an additional $10 million on January 9, 2026, bringing total outstanding principal to $60 million.
- Preliminary FY2025 Revenue: Expected between $56.5M and $56.7M (up ~10-11% YoY).
- Cash Position: Reported $75.7 million in cash and cash equivalents as of Dec 31, 2025.
- Clinical Trial Update: BENEFIT-HF trial expected to cost $20M-$30M over 5-7 years; potential market expansion from $10.5B to $30.5B if successful.
CVRx, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: November 5, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'emerging growth company'
CVRx, Inc. announced the appointment of Brent Binkowski as Chief Operating Officer, effective August 11, 2025. The filing also includes the release of financial results for the quarter ended June 30, 2025.
🚩 Red Flags
- Sign-on bonus includes a clawback provision (standard for micro-caps to mitigate risk, but noted).
📋 Key Facts
- Appointment of Brent Binkowski as COO, effective August 11, 2025.
- Binkowski's compensation includes a $405,000 annual base salary and a target cash incentive of 50% of base salary.
- Equity awards granted: 74,900 stock options and 16,600 restricted stock units (RSUs).
- A $50,000 sign-on bonus was approved, subject to a one-year clawback provision if terminated for cause or resignation.
- The company released financial results for the quarter ended June 30, 2025 via Exhibit 99.1.
CVRx, Inc. held its 2025 annual meeting of stockholders on June 3, 2025. The filing reports the election of two directors and the ratification of Grant Thornton LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 3, 2025.
- Kevin Ballinger elected to Class I director (15,182,085 votes 'For').
- Mitch Hill elected to Class I director (14,338,976 votes 'For').
- Stockholders ratified Grant Thornton LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- The company is classified as an emerging growth company.
CVRx, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal notice that a press release containing these results was issued on May 8, 2025.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025.
- Filing date: May 8, 2025.
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
CVRx, Inc. issued an 8-K to announce the release of preliminary financial results for the first quarter ended March 31, 2025.
📋 Key Facts
- The filing is a notice regarding the issuance of a press release containing preliminary Q1 2025 financial results.
- Report date: April 7, 2025.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
CVRx, Inc. filed an 8-K to announce the issuance of its financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: February 4, 2025
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
- Company is classified as an emerging growth company.
CVRx, Inc. announced preliminary financial results for the fourth quarter and full fiscal year 2024, reporting significant year-over-year revenue growth.
🚩 Red Flags
- Use of an at-the-market (ATM) offering to raise capital ($12.8M in Q4), indicating ongoing need for liquidity/dilution management.
📋 Key Facts
- Q4 2024 expected total revenue: $15.2M - $15.3M (up ~35% from Q4 2023's $11.3M).
- Full Year 2024 expected total revenue: $51.1M - $51.2M (up ~30% from FY 2023's $39.3M).
- Q4 2024 U.S. revenue component: $14.2M - $14.3M; European revenue: ~$1.0M.
- Issued 869,059 shares under an at-the-market (ATM) offering in Q4 2024 for gross proceeds of $12.8 million.
- U.S. active implanting centers increased to 223 as of Dec 31, 2024 (from 208 on Sept 30, 2024).
- Cash and cash equivalents stood at $105.9 million as of December 31, 2024.
CVRx, Inc. announced that CMS has assigned the Barostim procedure to New Technology Ambulatory Payment Classification (APC) 1580. This ensures continued Medicare reimbursement at approximately $45,000 per procedure through 2025.
📋 Key Facts
- CMS assigned Barostim procedure to APC 1580.
- The APC payment is approximately $45,000 per procedure.
- Reimbursement status is confirmed to continue into 2025 via the Medicare Hospital Outpatient Prospective Payment System final rule.
CVRx, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024 via a press release.
📋 Key Facts
- Report date: October 29, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing is an announcement of results under Item 2.02
- Company is classified as an 'emerging growth company'
CVRx, Inc. has drawn down the final $20.0 million tranche of its term loan facility with Innovatus Life Sciences Fund I, LP. This brings the total outstanding term loans under this specific facility to $50.0 million.
🚩 Red Flags
- Increased leverage: The company has drawn down its full capacity under this specific facility, increasing total debt to $50M.
- Reliance on private credit/life sciences funds which often carry higher interest rates or restrictive covenants compared to traditional bank debt.
📋 Key Facts
- Date of event: September 30, 2024
- Amount borrowed in current tranche: $20.0 million
- Lender: Innovatus Life Sciences Fund I, LP
- Total outstanding term loans under the facility: $50.0 million
- The draw represents the third and final tranche of the term loan facility.
CVRx, Inc. announced changes to its Board of Directors, including the appointment of two new independent directors and the resignation of one director.
📋 Key Facts
- Kevin Ballinger appointed as Class I Director, effective September 3, 2024; will serve on Nominating and Corporate Governance Committee.
- Mitch Hill appointed as Class I Director, effective September 3, 2024; will serve on Audit and Compensation Committees.
- Ali Behbahani resigned from the Board, effective at the close of business on September 2, 2024.
- The Board size increased to seven directors, effective September 3, 2024.
CVRx, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notification that a press release containing these results was issued on July 29, 2024.
📋 Key Facts
- Report date: July 29, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing is an announcement of financial results via press release (Exhibit 99.1)
- Company is classified as an 'emerging growth company'
CVRx, Inc. held its 2024 annual meeting of stockholders on June 4, 2024. The results included the election of three Class III directors and the ratification of Grant Thornton LLP as independent auditors.
🚩 Red Flags
- Approval of officer exculpation (Item 5.03) can sometimes be viewed as a measure to protect management from personal liability in shareholder litigation, though it is a standard corporate governance practice under Delaware law.
📋 Key Facts
- Annual Meeting held on June 4, 2024.
- Stockholders approved an amendment to the Certificate of Incorporation to allow for officer exculpation under Delaware law.
- Mudit Jain, Kirk Nielsen, and Martha Shadan were elected as Class III directors to serve until the 2027 annual meeting.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
CVRx, Inc. announced its participation in the William Blair 44th Annual Growth Stock Conference on June 5, 2024. During the presentation, the company reaffirmed its full-year and second-quarter 2024 financial guidance.
🚩 Red Flags
- Company acknowledges a history of significant losses which they expect to continue.
📋 Key Facts
- Reaffirmed FY 2024 total revenue guidance: $50.0 million to $53.0 million.
- Reaffirmed FY 2024 gross margin guidance: 83.0% to 85.0%.
- Reaffirmed FY 2024 operating expenses guidance: $92.0 million to $98.0 million.
- Reaffirmed Q2 2024 total revenue guidance: $11.3 million to $12.3 million.
CVRx, Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2024 and disclosed a specific compensatory arrangement.
🚩 Red Flags
- Mention of 'management transition' can sometimes signal internal instability, though here it is linked to a specific compensatory event.
📋 Key Facts
- Announced Q1 2024 financial results via press release on April 30, 2024.
- The Compensation Committee approved a $50,000 bonus for Paul Verrastro.
- The bonus was awarded in recognition of efforts related to management transition during Q1 2024.
CVRx, Inc. announced a leadership transition where Kevin Hykes will succeed Nadim Yared as President and CEO, effective February 12, 2024. The filing details the new CEO's compensation package and a consulting agreement for the outgoing CEO to ensure a seamless transition.
🚩 Red Flags
- CEO transition in a micro-cap environment can introduce strategic uncertainty during the handover period.
📋 Key Facts
- Kevin Hykes appointed President and CEO, effective February 12, 2024.
- Nadim Yared will retire as CEO and from the Board on February 11, 2024, transitioning to a consultant through December 31, 2024.
- New CEO compensation includes $640,000 annual base salary and a $150,000 cash sign-on bonus.
- New CEO will receive an inducement grant of 360,000 stock options.
- Outgoing CEO Nadim Yared will be paid $550 per hour for consulting services.
CVRx, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023. The filing serves as a formal notice that earnings data was released via press release on January 25, 2024.
📋 Key Facts
- Report date: January 25, 2024
- Reporting period: Quarter and year ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 containing the financial results.
- Company is classified as an 'emerging growth company'.
CVRx, Inc. announced the planned retirement of its President and CEO, Nadim Yared, following a deliberate succession process. Simultaneously, the company reported strong preliminary revenue growth for FY2023.
🚩 Red Flags
- CEO departure (though described as a planned retirement with a transition period).
📋 Key Facts
- CEO Nadim Yared has provided notice of plans to retire upon completion of a succession process.
- The Board is conducting a search for a new CEO with an executive search firm; Mr. Yared will remain in his role until a successor is appointed.
- Q4 2023 revenue expected: $11.2M - $11.3M (up ~56-58% YoY from $7.2M).
- Full Year 2023 revenue expected: $39.2M - $39.3M (up ~74-75% YoY from $22.5M).
- Active implanting centers increased to 178 as of Dec 31, 2023, up from 159 in Sept 2023.
- Cash and cash equivalents stood at $91 million as of December 31, 2023.